Filters
Revumenib, a novel potent, selective oral inhibitor of the menin-KMT2A interaction, demonstrated promising antileukaemic activity in children and adults with highly refractory acute leukaemia with KMT2Ar* or NPM1* mutation, a phase I dose-escalation study finds.
A single dose of nirsevimab administered before or during the respiratory syncytial virus (RSV) season provides protection against RSV lower respiratory tract infection (LRTI) hospitalization and very severe infection in infants, according to the preliminary results of a clinical trial conducted in real-world settings.
Children with Lennox-Gastaut syndrome (LGS) and Dravet's syndrome (DS) achieve improvements in both seizure management and nonseizure outcomes following treatment with cannabidiol (CBD)—a success echoed in their adult counterparts, as shown in a study presented at AAN 2023.
Individuals born large for gestational age (LGA) are more likely to develop obesity and metabolic syndrome later in life than those born appropriate for gestational age, suggests a study.
The dengue vaccine confers substantial protective benefit on children aged 10 to 15 years, reports a study in the Philippines, which was presented at the recent ESPID 2023.
New drug applications approved by US FDA as of 01-15 May 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Treatment with ataluren improves ambulatory function, as assessed by the 6-minute walk distance (6MWD) test, among boys with nonsense mutation Duchenne muscular dystrophy (nmDMD), according to the subgroup analysis of Study 041 trial presented at AAN 2023.
Self-compassion and relationship satisfaction play a significant role in the relationship between sexual functioning and child sexual abuse (CSA), a study has found.
A recent single-centre study, which reduced the birth weight (BW) threshold for bridging parenteral nutrition (PN) from 1,500 to 1,250 g, has found that PN was initiated in about one in four infants with a BW between 1,250 and 1,500 g.
Children with prior use of carbapenem are at increased risk of developing Stenotrophomonas maltophilia bloodstream infection (BSI), suggests a study. In addition, admission to the paediatric intensive care unit (PICU) due to BSI and prior glycopeptide use are significantly associated with the mortality rate in patients with S. maltophilia BSIs
